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Of a large body of literature reporting clinical outcomes
for patients maintained on peritoneal dialysis (PD), most
publications have focused on relatively short-term results.
Few reports have focused on long-term survival in PD
patients. Here, we present our experience with long-term
patient outcomes and further analyses of the trends in
demographics and clinical outcomes of 2301 end-stage
renal disease (ESRD) patients treated with continuous
ambulatory PD (CAPD) during a 25-year period (1981 –
2005) at our institute. Outcomes were analyzed for 1656
patients, excluding those younger than 15 years of age at
initiation of CAPD, those having less than 3 months’ follow-
up, or those who had been on hemodialysis or who received
a kidney graft before starting CAPD.
In the study patients, technique survival at 5 and 10
years was 71.9% and 48.1% respectively. Patient survival
was 69.8% and 51.8%. Mean age at the start of PD (50.4 ±
13.9 years vs. 44.2 ± 13.9 years, p < 0.01), ESRD incidence
as a result of diabetic nephropathy (30.5% vs. 19.5%, p <
0.01), and incidence of cardiovascular comorbidities
(26.6% vs. 20.5%, p < 0.01) were all significantly greater
in patients who started PD during the second half of the
study period (1993 – 2005) as compared with the first
half (1981 – 1992). A multivariate analysis adjusting for
these changes in demographics and comorbid conditions
revealed that PD therapy starting in 1993 – 2005 was
associated with a significant reduction in technique
failure [hazard ratio (HR): 0.65; p < 0.01] and mortality
(HR: 0.68; p < 0.01) as compared with the earlier period.
However, in subgroup analyses, technique survival was
not observed to be significantly improved in patients
with diabetes.
In summary, technique and patient survival have
significantly improved despite increases in patient age,
cardiovascular comorbidity, and ESRD caused by diabetes.
Although diabetes, older age, and cardiovascular
comorbidities are not factors that are easily modifiable to
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Continuous ambulatory peritoneal dialysis (CAPD)is an established treatment modality in patients
with end-stage renal disease (ESRD), and approxi-
mately 150 000 patients are being maintained on CAPD
worldwide (1). However, the decline of CAPD as com-
pared with hemodialysis (HD) has become evident, even
though many reports indicate that survival rates with
peritoneal dialysis (PD) are better than those with HD
during the first 2 – 3 years after dialysis initiation
(2,3). In Korea, CAPD was introduced in the early
1980s, and the technique has been widely used in many
centers. Currently, more than 8000 Korean patients
are maintained on CAPD. Some publications have re-
ported the outcome of CAPD in Korea (4,5), but re-
ports of long-term CAPD results are scarce. Recently,
we reported long-term outcomes for CAPD at our insti-
tute (6). Although ours was a single-center study, our
extensive and dedicated clinical experience showed
remarkable results. Here, we briefly discuss our long-
term clinical experience, particularly with regard to
survival rates and trends in the improvement of clini-
cal outcomes over 25 years.
PATIENTS AND METHODS
During 1981 – 2005, we initiated PD in a total of
2301 patients at our institute. After excluding patients
that had been younger than 15 years of age at initia-
tion of CAPD, that had had fewer than 3 months’ follow-
up, and that had been on HD or received a kidney graft
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Of the 1656 CAPD patients in the study, 912 (55.1%)
were men. Mean age of the patient population at the
start of CAPD was 48.9 ± 14.1 years, and mean PD dura-
tion was 46.0 ± 40.4 months (range: 3 – 226 months).
Diabetes was the most common cause of ESRD (27.8%),
followed by chronic glomerulonephritis (16.5%), and
hypertension (13.0%).
RESULTS
PATIENT OUTCOMES
The 1-, 3-, 5-, and 10-year technique survival rates
were 94.9%, 83.7%, 71.9%, and 48.1% respectively.
The main causes of technique failure were peritonitis
(72.3%), ultrafiltration failure (14.0%), mechanical
malfunction and leakage (7.3%), and exit-site and tun-
nel infection (3.4%). The 1-, 3-, 5-, and 10-year patient
survival rates were 93.4%, 81.5%, 69.8%, and 51.8%
respectively. Most deaths were the result of cardiovas-
cular disease (31.8%) or infection (27.1%).
TRENDS IN DEMOGRAPHICS AND CLINICAL OUTCOMES OVER
25 YEARS
Table 1 details trends in demographics, causes of
ESRD, and comorbid conditions of patients during the
first (1981 – 1992) and second (1993 – 2005) halves
of the study period. Mean age of patients at the start
of CAPD increased from 44.2 ± 13.9 years to 50.4 ±
13.9 years. Also, the proportion of patients over 60
years of age at CAPD initiation doubled from the first
to the second half of the study period. The proportion
of incident PD patients whose renal failure was caused
by diabetic nephropathy rose to 30.5% from 19.5%
during that time (Table 1).
Table 2 shows changes in clinical outcomes be-
tween the two halves of the study period. The tech-
nique survival rate was signif icantly improved in
patients who started PD in 1993 – 2005 as compared
with the patients who started in 1981 – 1992 (Figure
1, Table 2). Technique failure caused by peritonitis
declined significantly in the second half of the study
period (1993 – 2005) as compared with the first half
(1981 – 1992). Overall patient survival did not dif-
fer between the two per iods; however, mortality
attributable to cardiovascular diseases significantly
before the start of CAPD, we analyzed data relating to
1656 patients. Patients who recovered kidney func-
tion or who started CAPD for other reasons (such as
acute renal failure or congestive heart failure) were
also excluded.
TABLE 1
Trends in Demographics, Causes of End-Stage Renal
Disease (ESRD), and Comorbidities Between the
First and Second Halves of the Study Period
1981–1992             1993–2005
(n) (%) (n)         (%)
Patients (n) 410 1246
Sex (men:women) 242:168 670:576
Age (years) 44.2±13.9 50.4±13.9a
16–30 84 20.5 114 9.1a
31–45 127 31.0 324 26.0
46–60 149 36.3 499 40.1
>60 50 12.2 309 24.8a
Cause of ESRD
Diabetes 80 19.5 380 30.5a
CGN 77 18.8 196 15.7
Hypertension 40 9.8 176 14.1a
PKD 11 2.6 24 1.9
Others 28 6.8 60 4.8
Unknown 174 42.4 410 32.9a
Comorbidities
CVD 87 20.5 332 26.6a
Lung disease 3 0.7 12 1.0
Liver disease 11 2.7 29 2.3
Malignancy 7 1.7 26 2.1
a   p < 0.01 compared with 1981–1992.
CGN = chronic glomerulonephritis; PKD = polycystic kidney
disease; CVD = cardiovascular disease.
increased, and mortality attributable to infection
decreased (Table 2).
RISK ANALYSES FOR TECHNIQUE AND PATIENT SURVIVAL
Unadjusted univariate analysis showed no differ-
ence in mortality between patients who started CAPD
in 1993 – 2005 and those who started in 1981 – 1992
(Table 3). However, a multivariate Cox proportional
hazards regression model revealed that patient sur-
vival increased significantly when adjusted for age,
sex, diabetes status, and cardiovascular comorbidity
[Figure 1, Table 3; hazard ratio (HR): 0.68; p < 0.001].
In addition, male sex (HR: 1.28; p < 0.05), presence
of diabetes (HR: 2.68; p < 0.01), older age (HR: 1.06;
p < 0.01), and cardiovascular comorbidity at the start
of PD (HR: 2.66; p < 0.01) were all significantly asso-
ciated with an increased risk of death. Technique sur-
vival increased signif icantly from the f irst to the
second half of the study period even after adjustment
for those covariates. Only the presence of diabetes
was identified as a significant risk factor for technique
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failure in the multivariate analysis (Table 3; HR: 1.28;
p < 0.05).
When we conducted subgroup analyses by diabetes
status and age, we observed improved patient survival
in both diabetic and nondiabetic patients from the
1993 – 2005 cohort as compared with parallel groups
from the 1981 – 1992 cohort. However, the improved
survival in the 1993 – 2005 cohort  was more signifi-
cant in patients younger than 55 years of age at the
start of CAPD; improvement in patients older than 55
years was marginal [HR: 0.77; 95% confidence inter-
val (CI): 0.56 to 1.05].
Technique survival improved significantly in older
and younger patients alike. However, improved tech-
nique survival was not observed in patients with
diabetes (Figure 2).
DISCUSSION
Our long-term clinical experience demonstrate re-
markable CAPD outcomes over the 25 years starting
in 1981. Technique and patient survival rates alike
were higher as compared with rates reported earlier
(7–10). Moreover, the overall survival  rate for PD pa-
tients at our center is comparable to that for patients
maintained on HD in other Asian countries, includ-
ing Japan (11).
A noteworthy finding of the present study is the
significant improvement in both technique and patient
survival for patients who started PD in 1993 – 2005 as
compared with patients from the earlier half of the study
period, despite the increasing proportions of older
and diabetic patients. One reason for the improved tech-
nique survival was a decreased incidence of peritoni-
tis: we previously reported a lower overall peritonitis
rate as compared with rates in other countries. Moreo-
ver, peritonitis rates have been declining since the early
1990s at our center (6). Many studies have showed
that the Y-set and double-bag systems have contrib-
uted greatly to the reduction in the peritonitis rate
(12,13). Those two connection methodologies were
provided starting in the early 1990s and were used for
all PD patients at our institute starting in the mid-
1990s. We observed a significant fall in the rate of
gram-positive peritonitis from that time forward (6).
Accordingly, technique failure declined significantly
during 1993 – 2005 because of declines in peritonitis
TABLE 2
Clinical Outcomes in the First and Second Halves
of the Study Period
1981–1992 1993–2005
(n) (%) (n) (%)
Patients (n) 410 1246
5-Year patient survival 71.5 69.1
Cause of death
Cardiovascular 17 13.4 73 23.8a
Cerebrovascular 14 11.0 34 11.1
Infection 50 39.4 68 22.1a
Malignancy 6 4.7 14 4.5
5-Year technique survival 64.5 74.7a
Cause of technique failure
Peritonitis 149 79.7 167 66.8a
Ultrafiltration failure 20 10.7 41 16.4
Mechanical/leakage 8 4.2 24 9.6
ESI/tunnel infection 5 2.7 10 4.0
a   p < 0.05 compared with 1981–1992.
ESI = exit-site infection.
Figure 1 — (A) Technique survival and (B) patient survival for
the two halves of the study period (1981 – 1992 and 1993 –
2005), adjusting for age, sex, diabetes status, and cardiovascular
comorbidity. The technique and patient survival rates were both
significantly better in patients who started peritoneal dialysis
during 1993 – 2005 (solid line) than in patients who started
peritoneal dialysis during 1981 – 1992 (dashed line).
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and improvements in PD connection systems (Tables 2
and 3).
In addition, our study revealed that patient sur-
vival at our center was greater than that previously
reported for other centers and countries. The reason
for the superior patient survival rate at our center is
not yet fully understood. The relatively younger age
of patients at CAPD initiation and the lower propor-
tion of diabetic patients can account for only part of
our center’s superior outcome, age and diabetes hav-
ing generally been established to be the most impor-
tant and significant determinants of survival outcome
in CAPD patients. However, the mean age of new ESRD
patients initiating CAPD and the proportion of dia-
betic ESRD patients increased signif icantly during
the second half of the study period reported here
(Table 1). Even considering those changes, a multi-
variate analysis nevertheless showed a significant im-
provement in patient survival in the 1993 – 2005
cohort as compared with the 1981 – 1992 cohort—
an outcome not ver y dif ferent from that in the
unadjusted model (Table 3).
Interestingly, a number of studies reported a sur-
vival advantage for Asian ESRD patients over Caucasian
patients (11,14,15). Relevant to those findings are the
results of the Dialysis Outcomes and Practice Patterns
Study, which indicated that the relative risk for death
is significantly higher for HD patients in both Europe
and the United States as compared with HD patients in
Japan (16). Just as Japanese PD patients achieve
excellent results, with 5- and 10-year patient survival
rates being 67.4% and 48.6% respectively (11),
patients at our center show equally remarkable results.
But to truly determine if patient survival on PD is bet-
ter in Asian patients than in patients from Western
countries, further exploration is required.
To further elucidate which patients had the best
outcomes in the two halves of our study period, we
conducted subgroup analyses according to diabetes
status and patient age (Figure 2). Patient survival was
improved in the second half of the study period re-
gardless of diabetes status and age. Although survival
was not significantly better in older patients (those
over 55 years of age), it came close (p = 0.076). In
addition, technique survival was significantly better
in younger and older patients alike. However, improved
technique survival was observed only in nondiabetic
patients, in whom 5-year technique survival signifi-
cantly improved to 76.4% in 1993 – 2005 from 64.7%
in 1981 – 1992. In contrast, in diabetic patients, sur-
vival was not statistically different between the two
periods (58.8% in 1981 – 1992 vs. 64.6% in 1993 –
2005, p = 0.28).
An improvement in patient and technique survival
for CAPD patients with diabetes is a future challenge.
Prolonged use of conventional glucose PD solutions
may accelerate changes in per itoneal membrane
structure and function in patients with diabetes,
TABLE 3
Technique and Patient Survival by Multivariate Cox Proportional Hazards Model
Covariates         Unadjusted          Adjusteda
HR 95% CI HR 95% CI
Technique survival
Age (per 1-year increase) 1.00 0.99 to 1.00 0.99 0.98 to 1.01
Sex (women vs. men) 0.91 0.75 to 1.10 0.93 0.77 to 1.12
With diabetes (vs. without diabetes) 1.14 0.89 to 1.44 1.28 1.01 to 1.65b
CVD comorbidity (vs. no CVD comorbidity) 0.99 0.56 to 1.76 0.96 0.54 to 1.72
PD starting in 1993–2005 (vs. in 1981–1992) 0.66 0.54 to 0.80c 0.65 0.53 to 0.79b
Patient survival
Age (per 1-year increase) 1.07 1.06 to 1.08c 1.06 1.05 to 1.07c
Sex (women vs. men) 0.77 0.64 to 0.93c 0.78 0.65 to 0.95c
With diabetes (vs. without diabetes) 4.15 3.42 to 5.05c 2.68 2.16 to 3.31c
CVD comorbidity (vs. no CVD comorbidity) 4.82 3.63 to 6.42c 2.66 1.99 to 3.56c
PD starting in 1993–2005 (vs. in 1981–1992) 0.93 0.75 to 1.15 0.68 0.55 to 0.86c
a   Adjusted for age, sex, diabetes, and cardiovascular comorbidity.
b   p < 0.05.
c   p < 0.001.
HR = hazard ratio; CI = confidence interval; CVD = cardiovascular disease; PD = peritoneal dialysis.
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causing an increased incidence of peritonitis and ultra-
filtration failure. In this regard, the new bio-compatible
PD solutions containing lower levels of glucose degra-
dation products and the new non glucose, icodextrin-
based solutions are highly promising. Use of these newer
solutions may prevent or delay alterations in peritoneal
membrane structure and function in diabetic patients
during long-term PD (17–19).
The present study is limited by the exclusion of cer-
tain important factors that could influence clinical out-
comes, including details of comorbid conditions,
residual renal function, nutritional status, and perito-
neal transport characteristics, among others. A signifi-
cant number of patients who had undergone previous
HD or transplantation before initiating PD were excluded
from the analysis. In addition, our study was not a
multicenter study, and therefore a center-specific effect
(20) cannot be excluded. However, we believe that ours
is one of the largest cohort studies of CAPD patients. To
our knowledge, 25 years is the longest period of expe-
rience reported in the literature. The size and breadth
of the present study are clear strengths.
CONCLUSIONS
We found that patient and technique survival rates at
our center were higher than those previously reported
for other countries. Both rates improved significantly
over 25 years. Although diabetes, old age, and cardio-
vascular comorbidities are factors that are not easily
modifiable to improve PD outcomes, our results are
encouraging in an era of declining PD utilization.
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